A method (i) of identifying subjects with HER2-positive cancer that should be screened for brain metastasis; (ii) of identifying subjects with HER2-positive cancer that should receive treatment with a HER2-acting agent and a second form of cancer treatment; (iii) for determining an expected time to brain metastasis (TTBM) in a subject with a HER2-positive cancer; (iv) for determining the relative likelihood of whether a subject with a HER2-positive cancer is at risk for developing brain metastases; and/or (v) of determining if a subject with HER2-positive cancer is within in a subset of HER2-positive cancer subjects that should be screened for brain metastasis, comprising: (a) providing a biological sample of a tumor obtained from the subject's cancer; (b) measuring the amount of p95 protein in the biological sample; (c) determining whether the amount of p95 protein in the subject's sample is above a p95 cutoff; and (d) (i) indicating that the subject should be screened for brain metastasis if the amount of p95 protein is above the p95 cutoff; (ii) indicating that the subject should receive treatment with a HER2-acting agent and a second form of cancer treatment if the amount of p95 protein is above the p95 cutoff; (iii) indicating the subject's expected TTBM based on the incidence of brain metastasis over time in a reference population having p95 protein levels above or below the p95 cutoff; (iv) indicating that, if the amount of p95 protein in the biological sample are above the p95 cutoff, the subject is more likely to be at risk for developing brain metastases; and/or (v) indicating that the subject should be screened for brain metastasis if the amount of p95 protein is above the p95 cutoff. (a) providing a biological sample of a tumor obtained from the subject's cancer; (b) measuring the amount of p95 protein in the biological sample; (c) determining whether the amount of p95 protein in the subject's sample is above a p95 cutoff; and (d) (i) indicating that the subject should be screened for brain metastasis if the amount of p95 protein is above the p95 cutoff; (ii) indicating that the subject should receive treatment with a HER2-acting agent and a second form of cancer treatment if the amount of p95 protein is above the p95 cutoff; (iii) indicating the subject's expected TTBM based on the incidence of brain metastasis over time in a reference population having p95 protein levels above or below the p95 cutoff; (iv) indicating that, if the amount of p95 protein in the biological sample are above the p95 cutoff, the subject is more likely to be at risk for developing brain metastases; and/or (v) indicating that the subject should be screened for brain metastasis if the amount of p95 protein is above the p95 cutoff. (i) indicating that the subject should be screened for brain metastasis if the amount of p95 protein is above the p95 cutoff; (ii) indicating that the subject should receive treatment with a HER2-acting agent and a second form of cancer treatment if the amount of p95 protein is above the p95 cutoff; (iii) indicating the subject's expected TTBM based on the incidence of brain metastasis over time in a reference population having p95 protein levels above or below the p95 cutoff; (iv) indicating that, if the amount of p95 protein in the biological sample are above the p95 cutoff, the subject is more likely to be at risk for developing brain metastases; and/or (v) indicating that the subject should be screened for brain metastasis if the amount of p95 protein is above the p95 cutoff.